Bitterroot Bio, a leader in developing innovative medicines in the field of cardio-immunology, announced today that the Company will present results from the Phase 1 study of BRB-002 in healthy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback